tradingkey.logo

Amphastar Pharmaceuticals Inc

AMPH
View Detailed Chart

27.640USD

+0.200+0.73%
Close 09/19, 16:00ETQuotes delayed by 15 min
1.29BMarket Cap
9.54P/E TTM

Amphastar Pharmaceuticals Inc

27.640

+0.200+0.73%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.73%

5 Days

-1.50%

1 Month

-8.87%

6 Months

-0.79%

Year to Date

-25.56%

1 Year

-44.82%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
25 / 175
Overall Ranking
107 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
33.200
Target Price
+20.99%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 46.69% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 74.56.
Undervalued
The company’s latest PE is 9.82, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.09M shares, decreasing 8.58% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.67M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
Ticker SymbolAMPH
CompanyAmphastar Pharmaceuticals Inc
CEODr. Yongfeng (Jack) Zhang, Ph.D.
Websitehttps://amphastar.com/
KeyAI